Whatever the Court’s backlog may be, the salient point is that Teva would not have agreed to a 2-year delay in the Lovenox patent-infringement trial if Teva had a serious chance of getting FDA approval for generic Lovenox in the near future. Thus, I stand by my prior assertion on this topic.
Other than the ItalFarmaco connection, the drawn-out schedule of the Lovenox patent-infringement case is probably the best nugget of information to show that Teva’s Lovenox program is something of a sham.
Market Data 
Markets 
AI
